-
Promising Leukemia Drug Boosts Micromet
Saturday, June 11, 2011 - 11:09amShares of Micromet (NASDAQ: MITI), a biopharmaceutical company based in Rockville, Maryland, closed up 8.7% Friday. In a press release, the company said research suggests that its new antibody agent called blinatumomab, may be a useful weapon against acute lymphoblastic leukemia (ALL)....
Read More >> -
RBC Capital Upgrades Micromet To Outperform, $8 PT
Wednesday, April 6, 2011 - 8:17amRBC Capital has upgraded Micromet (NASDAQ: MITI) from Sector Perform to Outperform and has established an $8 price target.
Read More >> -
Piper Jaffray's Favorite Antibody Plays (SGEN, MITI, REGN)
Wednesday, January 5, 2011 - 8:50amPiper Jaffray has released a report that focuses on next-gen antibody companies. “Over the past several years, we have seen significant consolidation in the biotherapeutic space,” Piper Jaffray writes. “We expect this trend to continue due to the scarcity of antibody technologies and the longer...
Read More >> -
Piper Jaffray Reiterates Overweight Rating on Micromet (MITI)
Monday, November 22, 2010 - 10:59amPiper Jaffray reiterates its Overweight rating on Micromet (NASDAQ: MITI) based on the advancement and expansion of MITI's BiTE antibody pipeline. In a note to clients, Piper Jaffray writes, "Following a $70.5 million offering, Micromet now holds pro forma cash of $235 million. The cash should last...
Read More >>


